Evidence map›Paper›PMID 35848717›Full record

ArticleEuropean journal of pain (London, England)2022

Trends in opioid utilization in Hungary, 2006-2020: A nationwide retrospective study with multiple metrics.

Zsófia Engi, Ria Benkő, Gyöngyvér Soós, Délia Szok, Melinda Csenki, Emese Csüllög, Attila Balog, Dezső Csupor, Réka Viola, Péter Doró and 1 more

Abstract read
In one paragraph

Article in European journal of pain (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Global under- and overprescribing of drugs-a scoping review.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zsófia EngiInstitute of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary.
Ria BenkőInstitute of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary.
Gyöngyvér SoósInstitute of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary.
Délia SzokDepartment of Neurology, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary.
Melinda CsenkiDepartment of Oncotherapy, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary.
Emese CsüllögDepartment of Anesthesiology and Intensive Care, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary.
Attila BalogDepartment of Rheumatology and Immunology, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary.
Dezső CsuporInstitute of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary.
Réka ViolaInstitute of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary.
Péter DoróInstitute of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary.
Mária MatuzInstitute of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary.ORCID 0000-0002-7877-2399

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOpioid use is well documented in several countries: some countries struggle with overuse, whereas others have almost no access to opioids. For Europe, limited data are available. This study analysed Hungarian opioid utilization in ambulatory care between 2006 and 2020.

methodsWe obtained national drug utilization data on reimbursed opioid analgesics (ATC code: N02A) from a national health insurance database for a 15-year period. We investigated utilization trends, using three volume-based metrics [defined daily dose per 1000 inhabitants per day (DID), oral morphine equivalent per 1000 inhabitants per day, packages dispensed per 1000 inhabitants per year]. We stratified data based on administration routes, analgesic potency and reimbursement categories.

resultsTotal opioid utilization increased during the study period according to all three metrics (74% in DID) and reached 5.31 DID by 2020. Upward trends were driven by an increase both in weak and strong opioid use (79% vs. 53%). The most commonly used opioids were fentanyl (in the strong category; 0.76 DID in 2020) and tramadol (in the weak category; 2.62 DID in 2020). Overall, tramadol was also the most commonly used opioid throughout the study period. Oral administration of opioid medications was dominant. Based on reimbursement categories, musculoskeletal pain was becoming a more frequent indication for opioid use (1552% increase in DID), while opioid use for cancer pain declined significantly during the study period (-33% in DID).

conclusionsOur low utilization numbers might indicate underuse of opioid analgesia, especially for cancer pain. SIGNIFICANCE: This study was one of the recent opioid utilization studies using three volume-based metrics, covering a long time period. To our knowledge, this was also the first national, population level study describing opioid utilization in Hungary. National opioid utilization data suggested not an overuse but rather an underuse of opioid analgesics in a developed, Central European country.

Indexed as

Cancer PainOpioid-Related DisordersTramadolAnalgesics, OpioidDrug PrescriptionsDrug UtilizationHumansHungaryPractice Patterns, Physicians'Retrospective StudiesAnalgesics, OpioidTramadol

Identifiers

PMID35848717
PMCPMC9541344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.